leadf
logo-loader
viewArix Bioscience PLC

Arix Bioscience investee company Amplyx announces positive Phase 2 data

Fosmanogepix was also well tolerated with no treatment-related serious adverse events or discontinuations

Arix Bioscience PLC -

Arix Bioscience PLC (LON:ARIX), the biotech venture capital company, has noted an announcement from its portfolio company Amplyx Pharmaceuticals regarding a positive result from the Phase 2 clinical trial of its novel antifungal agent, fosmanogepix.

The trial, evaluating the safety and efficacy of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida, met its primary efficacy endpoint, demonstrating a treatment success rate of 80%.

Fosmanogepix was also well tolerated with no treatment-related serious adverse events or discontinuations, said Amplyx. In addition, fosmanogepix demonstrated potent in vitro activity against all Candida isolates obtained from patients in the study, including isolates resistant to other antifungal agents.

“We are very encouraged that fosmanogepix demonstrated a high rate of treatment success, including activity against resistant pathogens, and was well tolerated in patients with invasive Candida infections.

“Importantly, patients were able to easily transition from intravenous to oral formulations during their treatment,” said Michael R. Hodges, MD, chief medical officer of Amplyx.

Quick facts: Arix Bioscience PLC

Price: 158.75 GBX

LSE:ARIX
Market: LSE
Market Cap: £215.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE flounders as imminent Brexit talks loom

The FTSE is mixed this Tuesday despite the weaker pound. Sterling is still battling no deal Brexit fears as the UK Prime Minister Boris Johnson threatens that if no progress on the talks with the EU is made week, preparations for a no deal will be ramped up. Britain’s biggest sports retailer...

on 8/9/20

2 min read